In a severely obese adult with normal thyroid function, vitamin D 72 ng/mL, vitamin B12 705 pg/mL, folate 6.3 ng/mL, creatinine 1.12‑1.33 mg/dL (estimated glomerular filtration rate 92‑93 mL/min/1.73 m²), mild creatine kinase elevation and elevated homocysteine, what is the appropriate management?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Management of Low Folate with Elevated Homocysteine in Severe Obesity

You should supplement with folic acid 0.4–5 mg daily plus vitamin B12 0.02–1 mg daily to address the low folate (6.3 ng/mL) and elevated homocysteine, as this combination is safe, inexpensive, and targets the underlying metabolic abnormality regardless of whether cardiovascular benefit is proven. 1

Primary Issue: Low Folate Requiring Treatment

Your folate level of 6.3 ng/mL is borderline low to low-normal (typical reference range 2.7–17 ng/mL), and when combined with elevated homocysteine, this indicates functional folate insufficiency. The strong inverse correlation between serum folate and homocysteine levels means your elevated homocysteine is likely driven by inadequate folate 2.

Treatment Approach for Elevated Homocysteine

When homocysteinemia is present (as in your case), homocysteine-lowering treatment should be considered 1. The evidence shows:

  • Folic acid 400 mcg (0.4 mg) daily reduces plasma homocysteine by 25–30% 1
  • Adding vitamin B12 (0.02–1 mg daily) provides an additional 7% reduction 1
  • The combination of 0.5–5.0 mg folate plus 0.5 mg vitamin B12 can reduce homocysteine levels by approximately 12 µmol/L 2

Start with folic acid 1 mg daily plus vitamin B12 1 mg daily, as this dose is well-tolerated, safe, and effective for moderate hyperhomocysteinemia 1. Consider adding vitamin B6 (pyridoxine) 50–250 mg daily if homocysteine remains elevated after 3 months, as B6 is a cofactor in homocysteine metabolism 1.

Other Laboratory Findings: Reassuring

Vitamin D: No Action Needed

Your vitamin D level of 72 ng/mL is excellent—well above the sufficiency threshold of 30 ng/mL and in the optimal range. No supplementation needed 3.

Vitamin B12: Adequate

Your B12 level of 705 pg/mL is normal to high-normal (reference range typically 200–900 pg/mL). Despite this, you should still receive B12 supplementation as part of homocysteine-lowering therapy, since B12 works synergistically with folate in homocysteine metabolism 1, 2.

Kidney Function: Mild Concern

Your creatinine fluctuates between 1.12–1.33 mg/dL with eGFR >60–93 mL/min/1.73 m², indicating Stage 2 CKD (mild reduction in kidney function). This is relevant because:

  • Impaired renal function contributes to elevated homocysteine 1, 4
  • Each 1-unit decrease in eGFR is associated with higher homocysteine (β = -0.13) 4
  • Your kidney function is adequate enough that vitamin supplementation will still be effective 2

The creatinine variability (1.12–1.33) may reflect hydration status or muscle mass effects in severe obesity. Monitor creatinine every 6–12 months to ensure stability.

Creatine Kinase Elevation

The mild CK elevation likely reflects muscle breakdown related to obesity, metabolic syndrome, or physical activity patterns. This is not directly related to your vitamin status but warrants monitoring if progressive.

Why This Matters: Cardiovascular Risk

While the evidence does NOT definitively prove that lowering homocysteine reduces cardiovascular events 1, 2, the consensus is that treating the underlying vitamin deficiency is "at least not harmful" and addresses a correctable metabolic abnormality 1.

In severe obesity with elevated homocysteine:

  • Homocysteine correlates positively with waist circumference and triglycerides 4
  • Homocysteine correlates inversely with HDL cholesterol 5, 4
  • Folate shows positive correlation with HDL and apolipoprotein A-I (anti-atherogenic lipids) 5

Obesity-Specific Considerations

Severe obesity creates unique challenges:

  • Vitamin D is sequestered in adipose tissue (though yours is adequate) 6
  • Folate levels may be affected by dietary patterns common in obesity 5
  • Your Stage 2 CKD independently contributes to homocysteine elevation 1, 4

After bariatric surgery (if planned), routine metabolic and nutritional monitoring is mandatory, with particular attention to B vitamins 7.

Monitoring Plan

  1. Recheck homocysteine in 3 months after starting supplementation (target <10–15 µmol/L) 1, 8
  2. Recheck folate and B12 in 3 months to confirm adequacy
  3. Monitor creatinine/eGFR every 6–12 months to track kidney function
  4. If homocysteine remains elevated despite adequate folate/B12 levels, consider:
    • Adding vitamin B6 (pyridoxine) 50–250 mg daily 1
    • Checking for MTHFR genetic variants (if available and homocysteine >30 µmol/L) 1
    • Evaluating for other causes (medications, thyroid function—though your TSH is normal)

Common Pitfalls to Avoid

  • Don't use calcitriol or activated vitamin D to treat vitamin D "deficiency"—your vitamin D is already optimal 3
  • Don't expect homocysteine to normalize completely with supplementation alone, especially with Stage 2 CKD 2
  • Don't stop B vitamin supplementation even if homocysteine doesn't reach "normal" range—the goal is reduction, not necessarily normalization 2
  • Don't ignore the kidney function trend—worsening renal function will make homocysteine harder to control 1, 4

References

Research

Folate and Vitamin B12 in Morbid Obesity: The Influence of Folate on Anti-Atherogenic Lipid Profile.

International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition, 2020

Research

Decreased bioavailability of vitamin D in obesity.

The American journal of clinical nutrition, 2000

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.